Neurogene Inc. (NGNE) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	—	925.0K	—	—
Cost of Revenue	18.9M	3.2M	3.2M	3.3M	3.2M
Gross Profit	(18.9M)	(3.2M)	(2.3M)	(3.3M)	(3.2M)
Operating Expenses
R&D Expense	88.5M	75.0M	60.9M	44.4M	47.5M
SG&A Expense	32.1M	25.1M	22.6M	11.2M	9.0M
General & Admin Expense	26.0M	—	22.6M	11.2M	9.0M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(18.1M)	—	(3.2M)	(3.3M)	(3.2M)
Total Operating Expenses	102.5M	100.0M	80.3M	52.3M	53.3M
Cost and Expenses	121.3M	103.2M	83.5M	55.6M	56.5M
Operating Income (EBIT)	(121.3M)	(103.2M)	(82.6M)	(55.6M)	(56.5M)
Non-Operating
Interest Income	9.7M	11.5M	8.5M	3.0M	1.3M
Interest Expense	2.0K	5.0K	12.0K	12.0K	2.0K
Net Interest Income	9.7M	11.5M	8.5M	2.9M	1.3M
Other Non-Op Income/Expense	10.2M	12.9M	7.5M	19.3M	1.3M
Non-Operating Income (excl Interest)	(10.2M)	(12.9M)	(7.5M)	(19.3M)	(1.3M)
EBT (Pre-Tax Income)	(111.1M)	(90.4M)	(75.1M)	(36.3M)	(55.2M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(111.1M)	(90.4M)	(75.1M)	(36.3M)	(55.2M)
Earnings from Cont. Ops	(111.1M)	(90.4M)	(75.1M)	(36.3M)	(55.2M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(111.1M)	(90.4M)	(75.1M)	(36.3M)	(55.2M)
Per Share
Basic EPS	($5.51)	($4.24)	($4.28)	($2.83)	($4.30)
Diluted EPS	($5.51)	($4.24)	($4.28)	($2.83)	($4.30)
Revenue Per Share	$0.00	$0.00	$0.05	$0.00	$0.00
Shares
Basic Shares Outstanding	22.6M	21.2M	17.6M	12.8M	12.8M
Diluted Shares Outstanding	22.6M	21.2M	17.6M	12.8M	12.8M
Profitability Metrics
EBITDA	(106.3M)	(87.3M)	(71.9M)	(33.0M)	(52.0M)
D&A	4.8M	3.1M	3.2M	3.3M	3.2M
EBIT	(111.1M)	(90.3M)	(75.1M)	(36.3M)	(55.2M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026